Minimising the immunogenicity of biopharmaceuticals: Current status of monitoring immunogenicity across the R&D value chain

At the 2014 Exploratory Clinical Development World Europe, Sylvia Julien, Principal Scientist, Senior Project Leader Global Scientific Affairs and Strategic Sourcing, Ipsen,  gave a presentation on “Minimising the immunogenicity of biopharmaceuticals: Current status of monitoring immunogenicity across the R&D value chain. Download and learn: Immunogenicity and influencing factors Immunogenicity risk assessment, stage-based Conclusion and perspectives Download Presentation. Found this interesting? Join us …

Patient, Registries, Evidence, Value, Evidence Europe

How can patient registries add value to evidence based decision making?

At Evidence EU 2014, Dr. Päivi Hämäläinen, Director of Department of Information, National Institute of Health and Welfare, Finland, gave a presentation “How can patient registries add value to evidence based decision making?” Dr. Päivi Hämäläinen’s presentation depicts her theoretical vision: data is created during patient visits to care and can be secondarily used for research, planning and decision making. Download and …

Disease, Value, Registries, Decision making, Evidence, Evidence Europe

How Can Disease Registries Add Value to Evidence Based Decision Making?

At Evidence EU 2014, Steve Cunningham Consultant & Honorary Reader in Paediatric Respiratory Medicine, NHS, gave a presentation on “How Can Disease Registries Add Value to Evidence Based Decision Making?” Download and learn:  Case Identifier Registry Detailed Case Registry Large Disease Registry Current Definitions of Evidence Quality Evidence Quality -GRADE System Detailed Observational Data Download presentation Found this interesting? Join us at …

Value, drugs, payers

How Do You Demonstrate Value For Innovative Drugs To Payers?

  At Evidence EU 2014,  Prof. Dr. Markus Kosch, Pfizer Oncology, Portfolio Lead Europe, Africa/Middle East, Pfizer, gave a presentation on “How Do You Demonstrate Value For Innovative Drugs To Payers?” Download and learn: Value of innovation to public health PFS vs. OS the “wrong comparator” –can STC help? Real world data Download presentation Found this interesting? Join us at …

Value, European, Healthcare, Market

How to develop a compelling value proposition in the current European healthcare market

At Evidence EU 2014, Caroline Gadd, Otsuka Pharmaceuticals, gave a presentation on “How to develop a compelling value proposition in the current European healthcare market”. Gadd’s presentation highlights the importance of value proposition, demonstrating that a successful proposition is moving towards a customer centric approach as well as being able to support the whole market. Download and Learn: The value proposition as …

value, assessment

Value based assessment: NICE’s role

At Pharma Pricing & Market Access Europe 2014, David Haslam, Chairman, NICE, gave a presentation on “Value based assessment: NICE’s role” Haslam’s presentation discussed  incorporating burden of illness and wider societal impact into NICE’s technology assessment methods. Download and learn: Value Based Assessment NICE’s current approach Costs and benefits New DH terms of reference Approaches to appraising the impact of technologies …

observational research, payer, development, value, outcomes research, evidence europe

How can observational research be used to improve value development?

  At Evidence EU 2014, Clément François, Global Outcomes Research, Lundbeck gave a presentation on “Meeting payers’ needs: How can observational research be used to improve value development?” This presentation discusses the use of observational data through the different phases of development, as well as the different data sources for different objectives-from small dataset to large automated health care database. …

Download: Payer Engagement and Preparing Information to Support Value Proposition

Demonstrate value and improve payer engagement with tips from Jorge Arellano, MSc, MPhil, Director Global Health Economics, Amgen. In his presentation, given at Evidence USA 2013, he discusses these topics and more. Download to learn: Evidence Generation: The Process Evidence Generation: Key Deliverables Payers input Understanding Your Payer(s) Download presentation Discover how pharma, payers and patients are utilizing real world …

Download: Evidence generation vs Value creation

At last year’s Market Access USA event, Chris O’Neill, CEO, Curo Consulting gave a presentation entitled “Evidence generation vs. Value creation” – on moving from clinical data to an understanding of how a therpay can positively affect Payer Disease Management strategy. Download his presentation to learn: What are you trying to achieve? How do you use your data? What Payers …